Background: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. Objective: To develop consensus statements for all domains of DAT. Design, setting, and participants: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives. Robust methods regarding what constituted the consensus were strictly followed. Results and limitations: A total of 109 HCPs and 16 patients completed both survey rounds. Of 129 statements in the survey, consensus was achieved in 66 (51%); the rest of the statements were discussed and voted on in the consensus meeting by 32 HCPs and three patients, where consensus was achieved in additional 27 statements (43%). Overall, 93 statements (72%) achieved consensus in the project. Some uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low-risk disease, and the role of multiparametric magnetic resonance imaging in determining disease stage and aggressiveness as a criterion for inclusion and exclusion. Conclusions: Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials. Patient summary: We undertook a project aimed at standardising the elements of practice in active surveillance programmes for early localised prostate cancer because currently there is great variation and uncertainty regarding how best to conduct them. The project involved large numbers of healthcare practitioners and patients using a survey and face-to-face meeting, in order to achieve agreement (ie, consensus) regarding best practice, which will provide guidance to clinicians and researchers.
1.
Introduction Deferred treatment with curative intent (ie, deferred active treatment [DAT] ) has emerged as a feasible alternative to standard radical interventions for low-risk localised prostate cancer [1] [2] [3] . This includes active surveillance or active monitoring, whereby patients are not curatively treated immediately but instead are reassessed and monitored at regular intervals, and involves a choice by a patient following counselling with their physician, and alternative treatment options may be considered at a future time point. Large, prospective studies are currently underway, and mediumterm outcomes appear to be promising [4, 5] . However, clinical practice guidelines (CPGs) [6] often acknowledge the significant heterogeneity inherent in deferred treatment strategies, with protocols differing in patient eligibility, selection and recruitment, disease monitoring and reassessment, outcome definition and measurement, and triggers for reclassification and change in management. In short, there is uncertainty regarding the definition of eligible patients and the optimum follow-up strategies. Although attempts have been made to standardise definitions and terminology via consensus methods [7] , there have been no successful projects that harness clinical and patient expertise aiming to standardise practice comprehensively.
Consequently, the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations (Supplementary material) commissioned and undertook a project to develop consensus statements for DAT. The project was unique and novel in its use of protocol-driven consensus methods [8] . The specific objectives were to achieve consensus on the following domains: (1) criteria for patient selection, inclusion, and exclusion; (2) nature and timing of investigations and assessments during monitoring and follow-up; (3) criteria and thresholds for reclassification and change in management; and (4) type of outcome measures that should be prioritised. The study findings will be incorporated into international CPGs issued by the EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel and collaborators, and will guide and inform clinical practice and further research.
Material and methods
The protocol outlining the detailed methods underpinning the project has been published [8] . An overview of the study is depicted in Fig. 1 . The project was divided into three phases, lasting 12 mo. Phase 1 was a systematic review of current DAT practice [9] , the results of which are summarised in Tables 1-4 findings were used to inform a list of statements, and organised into domains and subdomains reflecting the aspects of DAT (ie, patient eligibility and recruitment, follow-up and monitoring, reclassification, and outcome measures).
In phase 2, the list of statements was incorporated into an online questionnaire as part of a two-round iterative Delphi survey. An international panel of participants including healthcare practitioners (HCPs; ie, urologists, medical and clinical/radiation oncologists, radi- Table 1 -Summary of systematic review findings (total n = 282 studies): criteria within the domains of inclusion, monitoring, reclassification, and outcome measures. In the online questionnaire, participants were presented with statements and asked to rate their strength of agreement on a scale of 1 (strongly disagree) to 9 (strongly agree). Participants could also suggest additional statements for incorporation into the following round. In round 2, participants were provided with information regarding their own score from round 1 as well as a summary of the scores for the entire cohort, and could either revise or retain their original scores. Thresholds regarding what constituted "consensus agreement" and "consensus disagreement" were specified a priori [8] . "Consensus agreement" was defined as 70% of participants scoring a statement as "strongly agree" (7) (8) (9) and <15% of participants scoring as "strongly disagree" (1) (2) (3) . Conversely, "consensus disagreement" was defined as statements scored as "strongly disagree" (score 1-3) by 70% of participants and "strongly agree" by <15% of participants (7) (8) (9) . All other statements not falling in the above categories will be classified as equivocal. The decision to use 70% as a threshold was based on prior studies and consensus method research [10] [11] [12] [13] .
Phase 3 consisted of a 1-d face-to-face consensus group meeting attended by representatives from all stakeholder groups, and chaired by a nonvoting clinician and nonvoting methodologist. Participants were sampled from those who completed both rounds of the Delphi survey. All participants were provided with a personalised printout containing a reminder of how they scored each statement in both rounds of the Delphi, and were given the summary of group results for all statements.
All statements not achieving consensus in phase 2 were discussed, reviewed, and voted upon by participants, using the same consensus thresholds from phase 2, using live voting software [8] . At the end of phase 3, a final list of consensus statements organised according to the domains of DAT were ratified by the consensus group participants and project steering group.
Results

Delphi survey
Round 1 of the Delphi survey was generated from the systematic review findings (Supplementary material). A total of 127 statements were organised under the following domains and subdomains: (1) A total of 180 HCPs involved with DAT were identified through international specialist societies (Supplementary material) and invited to participate. Fifty patients identified through patient advocacy organisations (Supplementary material) were invited to complete the patient-relevant parts of the survey (ie, outcome measures that should be prioritised). Two additional statements suggested by the participants were added to the questionnaire in round 2 (Supplementary material), bringing the total number of statements to 129. In total, 126 HCPs (70% of those invited) and 29 patients (58% of those invited) completed round 1, and 109 HCPs (61% of those invited) and 17 patients (34% of those invited) completed both rounds of the survey. The attrition rates between rounds 1 and 2 were 14% for HCPs and 41% for patients. The supplementary material outlines the list of Delphi participants organised by the stakeholder group (ie, HCPs or patients), including details such as name, speciality, and country of residence for HCPs, and previous treatment, age, and country of residence for patients. Table 5 summarises the characteristics of all Delphi participants completing both rounds of the survey, based on stakeholder groups, speciality (or relevant treatment for patients), age (for patients only), and country of residence. Table 6 summarises the survey results for all statements, organised according to consensus status (ie, consensus, near consensus, divergent opinions, or equivocal/unclear). In summary, there was consensus on 66 statements (51%) from the Delphi survey. The remaining 63 statements were brought forward for review, discussion, and voting in phase 3, to see if consensus could be achieved on them. 
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3.2.
Consensus group meeting
The consensus group meeting was held in Amsterdam, The Netherlands on November 9, 2018 during the 10th European Multidisciplinary Congress on Urological Cancers (ie, EMUC 2018). The meeting was attended by 35 voting participants (32 HCPs and three patients) and chaired by a nonvoting clinician and a nonvoting methodologist. Table 7 summarises the characteristics of consensus meeting participants based on stakeholder group, speciality, and country of residence. Table 9 summarises all the consensus statements obtained from all phases of the study. In total, 93 statements out of a total 129 (72%) achieved full consensus. The majority of these were achieved from the Delphi survey (71%), whilst the consensus group meeting contributed 29% to the consensus statements. Of the consensus statements, 53% were "consensus agree", whilst 48% were "consensus disagree". Consensus was achieved in at least 65% of statements across all domains across the Delphi and consensus meeting process. Table 10 lists all clinical practice recommendations based on the consensus statements.
Discussion
Principal findings
This project explored and defined key areas of controversy and uncertainty covering all the main domains of DAT, a large undertaking not previously attempted on this scale using transparent methodology. A mixed method approach was used to investigate this pressing problem, incorporating a systematic review, a two-round Delphi survey, and a face-toface consensus meeting with international participation from key stakeholders. The systematic review confirmed the scale and scope of the problem, highlighting significant heterogeneity, inconsistency, and variability in clinical practice across all domains in contemporary studies of DAT. Given such heterogeneity, it is not surprising to note that currently, there are no conclusive data on how different DAT strategies compare with one another and which strategy, definition, and threshold should be adopted in clinical practice and clinical trials. Although several seminal randomised controlled trials investigating the effectiveness of observation [1, 2] or active monitoring [3] as a management strategy for localised prostate cancer in comparison with active curative treatment have been published, these studies do not represent current practice of DAT, which has continued to evolve over the past 15 yr, especially with the introduction of new technology such as mpMRI scan into the patient care pathway, changes in the reporting of prostate cancer grade, and more accurate ways of performing prostate biopsies (including MRI-targeted biopsies or transperineal template biopsies). There is, therefore, an urgent need to provide guidance to clinicians, patients, researchers, and policymakers, and in the absence of high levels of evidence, the only available option is to issue consensus statements using robust, transparent, and reproducible methods. Our project set out to achieve this objective, and ultimately consensus was achieved in >72% of statements covering all the domains of DAT; the results will provide the basis for international guidance and drive the research agenda for the immediate future. The main recommendations based on the consensus statements are listed in Table 10 .
4.2.
Relevance and impact of study findings on clinical practice and research
Our study, with participation from HCPs and patients, has provided the basis for conduct of DAT. Consensus statements represent the lowest level of evidence (ie, level 5) on the evidence-based medicine hierarchy [14] , but in areas where there is low certainty and conflicting evidence, they represent a pragmatic basis for interim guidance. Consensus statements should be regarded as a starting point for clinicians and researchers to guide studies that will provide higher-quality evidence and increase certainty. Evidence is never complete; it is ever evolving, and correspondingly recommendations require updating as necessary. Using our consensus statements as a basis for informing and guiding the conduct of DAT, there is a need for clinicians to prospectively collect and audit data on DAT in routine clinical practice, and for researchers and trialists to conduct clinical trials or prospective comparative studies so that clinical effectiveness data can be obtained. In this context, initiatives such as PIONEER [15] and the Movember Foundation's Global Action Plan Active Surveillance (GAP3) project, which aims to establish a global prospective database [16] , represent important initial steps. Our results may be juxtaposed with those of other studies with overlapping aims. Bruinsma et al [7] used consensus methods to develop statements for active surveillance primarily aimed at standardising terms and definitions. The authors published a list of 61 items as a glossary of terms and definitions, whereas our study provides practical guidance for programmes of DAT. Both studies are complementary. MacLennan et al [12] used Delphi Disagree E U R O P E A N U R O L O G Y 7 6 ( 2 0 1 9 ) 7 9 0 -8 1 3 [12] core outcome set, providing confidence that men with localised prostate cancer and the HCPs who treat them, regarded the same outcomes as important in two separate samples. More recently, Merriel et al [17] published consensus statements on current best practice of active surveillance in the UK. The statements were developed by a multidisciplinary group of 27 members consisting of clinical experts and patient experts, informed by a review of the literature, existing guidelines and protocols used by UK urology departments, and survey data from men with localised prostate cancer. The final consensus statements were then issued by a subgroup of the panel (n = 14) in a face-to-face meeting. There are clear similarities between both projects, with both being informed by a review of the literature, and statements were developed by a multidisciplinary panel of clinicians and patients covering similar domains. However, there are major differences. It was unclear whether Merriel et al's [17] project was based on an a priori protocol for the systematic review (eg, Preferred Reporting Items for Systematic Reviews and Meta-analyses [PRISMA]) and for the consensus phases; the methods, processes and rules underpinning the consensus process, its definitions and how they were developed and achieved were not described. Our project was more international in scope, involved a larger multidisciplinary panel (n = 125) and was protocol-driven. We believe these are essential elements in any consensus endeavour which minimise bias, arbitrariness, and subjectivity, whilst enhancing rigour, transparency, and reproducibility. Nevertheless, there is overlap between the findings of both projects across all domains, and there are no major contradictory findings; as such both projects could be regarded as complementary.
Strengths and limitations
The study used robust, transparent and reproducible methods based on an a priori protocol. The study was international and contemporary in scope, involving patients and a large panel of HCPs purposively sampled from a broad range of disciplines, all of whom are stakeholders in DAT. A two-step, multi-phase consensus building process based on an iterative Delphi survey and consensus group meeting using anonymous voting techniques was employed, all of which enhanced internal validity. High external validity was achieved by ensuring that the survey items were informed by a systematic review of the literature, which was undertaken according to PRISMA guidelines. In terms of limitations, the project was designed to be pragmatic and practical for participants. Statements had to be brief and concise, and although participants rated their judgements on a scale, decisions were essentially binary in nature (ie, disagree or agree). Consequently, it was not possible to address all elements of uncertainty regarding DAT. In particular, the decision-making process regarding patient inclusion or exclusion or reclassification often involves a complex interplay between multiple factors and variables. The relative weighting placed on each variable as one or more variables change within and across patients, and how this affects the decision-making process for patients and clinicians are difficult to conceptualise and address meaningfully in a consensus-finding study. Secondly, within the HCPs' group, there was a higher ratio of urologists compared with other specialists, in both the Delphi survey and consensus group meeting. However, this reflects contemporary practice, whereby patients within DAT programmes are managed mostly by urologists. Additionally, there was an unusually high attrition rate within the patient group between rounds 1 and 2 of the Delphi survey (41%). However, the outcome of all statements rated by patients remained stable between rounds 1 and 2, hence suggesting that the attrition had minimal impact on the consensus outcome. There is also a small risk of introducing sampling error in terms of failure to achieve a balance between contrasting attitudes regarding active surveillance. However, through purposive sampling of a large number and a wide range of clinical practitioners involved in active surveillance, diverse opinions regarding active surveillance would have been achieved and hence minimising this risk. The choice of a threshold for defining consensus (ie, 70% in our study) merits a brief discussion. It may be argued that this is an arbitrary figure. However, our decision to use this threshold was informed by the methodological literature and through experience in previous consensus research conducted by members of the project steering group [12, 13, 18] . Many consensus projects define consensus as 70% of the participants choosing scores 7-9 and <15% choosing scores 1-3 (or vice versa) on a 9-point Likert scale, in order to account for the majority opinion whilst not dismissing divergent opinions [10, 11, 19] . The major emphasis in consensus methodology resources is that any threshold must have been judiciously selected, justified, and described a priori [20, 21] . A higher threshold of 80% or 90% gives undue influence to outlier opinions and would have significantly reduced the number of items reaching consensus, which seriously impairs the study's usefulness in clinical practice and research.
Lastly, the study did not achieve consensus on all statements, with 36 items (28%) failing to reach consensus, although 24 items from this group (ie, 67% out of the total number of statements not reaching consensus) achieved near consensus (Table 8 ). This reflects persisting uncertainty even amongst experts and specialists in the field, which can be resolved only through assessment of robust data from comparative studies from which higher levels of evidence can be obtained.
4.4.
Areas for further research
We highlight persisting uncertainly and areas for further study. Firstly, for DAT eligibility, there is a need to improve determination of life expectancy more accurately and on an individualised basis. Presently, a combination of approaches and strategies are employed, but they apply on a general rather than an individual level. A potential way forward may include studies exploring the creation of nomograms or actuarial tables integrating essential elements influencing life expectancy, such as age, ethnicity, social class, occupation, family history, specific comorbidities, smoking status, and so on. Secondly, as our project has shown, certain thresholds remain contentious. For instance, thresholds beyond which disease extent on biopsy ought to lead to exclusion of patients with lowrisk disease, or the role of mpMRI in determining disease stage and aggressiveness as a criterion for inclusion or exclusion into DAT programmes, require data from prospective, well-designed studies, incorporating diagnostic accuracy elements and allowing synthesis of evidence regarding clinical effectiveness. In particular, the definition of "high disease extent" based on biopsy characteristics remains problematic, although there was consensus on its importance. The role of a negative confirmatory biopsy was also not adequately explored in our study, and hence it deserves further study. In addition, since decision making for clinicians and patients regarding DAT should be individualised, there is a need to better understand how the complex interaction between multiple factors influences decision making, especially in terms of relative weighting placed on different variables and their tradeoffs; this could be explored through studies utilising discrete choice experiments [22] . In terms of monitoring and follow-up, there was no consensus regarding the role of per-protocol mpMRI or per-protocol repeat biopsies (ie, untriggered), or on their frequency and timing. The lack of consensus on the need for protocol-mandated (ie, untriggered) repeat biopsies is particularly striking because many contemporary prospective studies on DAT include them. Although we found consensus regarding repeat biopsy being required if there was a change in mpMRI, digital rectal examination progression, or PSA progression, it has to be acknowledged that the sensitivity of these triggers for higher-grade disease remains unproven. The evolving role of mpMRI in detecting clinically significant disease in place of biopsy is promising, as are new biomarkers (reviewed in the study of Loeb et al [23] ), including serum markers (eg, Prostate Health Index and 4 K score), urinary markers (eg, Prostate Cancer Antigen 3, or PCA3), and tissue markers (eg, genomic profiling). Once data on these promising diagnostic interventions mature, future studies should integrate them into nomograms predicting the probability of reclassification. In addition, given the current heterogeneity in practice, there is a need to standardise the risk categories and follow-up strategies in large prospective studies. Lastly, the findings from our study will improve and direct the standardisation of undertaking DAT in routine clinical practice and research. Clinicians should use them to carefully design their DAT protocols such that comparative clinical effectiveness data can be prospectively collected and the results audited regularly. Researchers should follow our guidance, and perform clinical trials or prospective cohort studies comparing different DAT protocols against each other and against immediate curative interventions.
Conclusions
The EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel, in partnership with other leading guideline authorities and patient advocacy organisations (Supplementary material), undertook an ambitious project using a novel and transparent approach in this setting to develop consensus statements for all domains relating to DAT, to standardise clinical practice and research. Protocol-driven, robust, and transparent methods were utilised. Consensus was achieved on 93 out of 129 statements (72%), covering the domains of criteria for patient selection, inclusion and exclusion (including patient and disease characteristics, imaging criteria, and type of biopsies), nature and timing of investigations and assessments during the period of monitoring and follow-up (including PSA measurements, clinical examination, repeat imaging and repeat biopsies), criteria and thresholds for reclassification and change in management, and type of outcome measures that should be prioritised. The findings will guide and inform routine clinical practice and research by being incorporated into guidelines issued by the EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel and partner organisations, until higher levels of evidence emerge through prospective comparative studies and clinical trials.
